WEDNESDAY 11th FEBRUARY 2015 COMMENCING 10.30 AM
AT THE ANGEL HOTEL, ABERGAVENNY, NP7 5EN

AGENDA

1. Welcome and introduction
2. Apologies
3. Declarations of interest
4. Minutes of previous meeting

To protect commercial confidentiality, the first appraisal will be conducted in private.

5. Appraisal 1: Full Submission (WPAS)
   Aflibercept (Zaltrap®) in combination with irinotecan/5 fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin containing regimen

The meeting will now open to the public (approx 11.15am)

6. Chairman’s report (verbal update)

7. Appraisal 2 - Full Submission
   Lurasidone (Latuda®) for the treatment of schizophrenia in adults aged 18 years and over


10. NPIs 2015–2016 Supporting Information for Prescribers


Appendices

1/AWMSG/0215
2/AWMSG/0215
3/AWMSG/0215
4/AWMSG/0215
5/AWMSG/0215
6/AWMSG/0215
7/AWMSG/0215
12. **Appraisal 3: Full Submission**  
Umeclidinium/vilanterol (as trifenate) (Anoro® Ellipta®) for maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease  
8/AWMSG/0215 Appendices

13. Feedback from AWPAG Meeting 10\(^{th}\) December 2014  
9/AWMSG/0215

14. Respiratory Prescribing Analysis with Cluster Level Comparators  
10/AWMSG/0215

15. All Wales Advice on the Role of Oral Anticoagulants – Implementation Documents  
11/AWMSG/0215

16. Eculizumab for treating atypical haemolytic uraemic syndrome  
12/AWMSG/0215

Date of next meeting:  
Wednesday 25\(^{th}\) March 2015 at the Angel Hotel, Abergavenny